Table 1.
Demographics.
| LuTRs (n = 57) | (n = 57) | |
|---|---|---|
| Age, median (IQR) | 55.5 (46.5–58.25) | 55 (44.0–64.00) |
| Sex, female n (%) | 35 (61) | 34 (60) |
| Time in years between lung organ transplantation and vaccination, median (IQR) | 7 (4–11) | NA |
| Immunosuppressive therapy including prednisone (n, %) | 57 (100) | NA |
| Immunosuppressive therapy including tacrolimus (n, %) | 56 (100) | NA |
| Immunosuppressive therapy including MMF/MPA n (%) | 47 (83) | NA |
| Immunosuppressive therapy including everolimus n (%) | 11 (19) | NA |
| Immunosuppressive therapy including ciclosporine n (%) | 1 (2) | NA |
| Therapy combination (n, %): | ||
| Tacrolimus, MMF/MPA, prednisone | 39 (68) | NA |
| Everolimus, tacrolimus, MMF/MPA, prednisone | 7 (12) | NA |
| Tacrolimus, prednisone | 6 (11) | NA |
| Everolimus, tacrolimus, prednisone | 3 (5) | NA |
| Everolimus, tacrolimus | 1 (2) | NA |
| Ciclosporine, MMF/MPA/prednisone | 1 (2) | NA |
| Therapy number n (%): | NA | |
| 2 Agents | 7 (12) | NA |
| 3 Agents | 43 (75) | NA |
| 4 Agents | 7 (12) | NA |
| Drug levels (median, IQR): | ||
| Ciclosporine (n = 1) | 120 | NA |
| Everolimus (n = 8) | 3.4 (2.7–3.6) | NA |
| Tacrolimus (n = 52) | 5.6 (4.3–6.8) | NA |
| Dose prednisone (median, IQR, n = 56) | 5 (5–5) | NA |
| Vaccine n (%) 2 doses n (%) | 57 (100) | 57 (100) |
| mRNA-1273 | 2 (4) | 0 (0) |
| BNT162b2 | 55 (96) | 57 (100) |
| Vaccine n (%) 3 doses n (%) | 24 (42) | 53 (93) |
| mRNA-1273 | 2 (8) | 2 (4) |
| BNT162b2 | 19 (80) | 51 (96) |
| ChAdOx1 nCoV-19 | 2 (8) | 0 (0) |
| Ad26.COV2.S | 1 (4) | 0 (0) |
Mycophenolate mofetil/mycophenolic acid (MMF/MPA); Not Applicable (NA).